Increase in Number of Shares and Votes in Vicore Pharma

The new shares were delivered to participants in three board incentive programs, diluting existing holders.

Rhea-AI Summary

Vicore Pharma (VCRE) increased its outstanding shares and votes by 118,916 following warrant exercises for participants in board incentive programs. The issuance followed the exercise of 117,737 share awards entitled to 118,916 shares under Board LTIP 2023, Board LTIP 2024 and Board RSU 2025.

As of September 30, 2026, total registered shares and votes stood at 281,644,509. Share capital increased by 59,457.999424 SEK to a registered total of 140,822,253.132817 SEK.

Positive

• None.

Negative

• Minor point118,916 new shares issued through board incentive awards dilute existing holders.

Key Figures

Share awards exercised: 117,737 share awards Shares added: 118,916 shares Share capital increase: 59,457.999424 SEK +2 more

Share awards exercised

117,737 share awards

Incentive programs

Shares added

118,916 shares

Increase in outstanding shares and votes

Share capital increase

59,457.999424 SEK

Increase following the share awards

Registered shares and votes

281,644,509

Total as of September 30, 2026

Registered share capital

140,822,253.132817 SEK

Total as of September 30, 2026

Key Terms

warrants, share capital, orphan drug, fast track designation, +1 more

5 terms

warrants financial

"following the exercise of warrants with subsequent delivery of shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

share capital financial

"the share capital by 59,457.999424 SEK"

Share capital is the total amount of money a company raises by selling pieces of itself, called shares, to investors. It’s like a company’s savings from many owners, which helps fund its growth and operations. This money matters because it shows how much the company has raised from shareholders and how it’s financed its business.

orphan drug regulatory

"received Orphan Drug and Fast Track designation"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track designation regulatory

"received Orphan Drug and Fast Track designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

idiopathic pulmonary fibrosis medical

"including idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to participants in the incentive programs Board LTIP 2023, Board LTIP 2024 and Board RSU 2025. The shares were issued through the exercise of 117,737 share awards, which are entitled to 118,916 shares.

Through the share awards, the number of outstanding shares and votes increased by 118,916 and the share capital by 59,457.999424 SEK. As of today, the total number of registered shares and votes amounts to 281,644,509. Furthermore, the registered share capital amounts to 140,822,253.132817 SEK.

For further information, please contact:
Hans Jeppsson, CFO, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

This information is information that Vicore Pharma Holding is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-09-30 09:00 CEST.

Attachments
Increase in number of shares and votes in Vicore Pharma

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares and votes does Vicore Pharma have after the incentive award exercises?

Vicore Pharma had 281,644,509 registered shares and votes as of September 30, 2026. The warrant exercises increased outstanding shares and votes by 118,916.

Which Vicore Pharma incentive programs accounted for the new shares?

The shares were delivered to participants in Board LTIP 2023, Board LTIP 2024 and Board RSU 2025. A total of 117,737 share awards were exercised, entitling participants to 118,916 shares.